Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab, nab-paclitaxel, and S-1 in advanced biliary tract adenocarcinoma
NCT07719738Phase 2Completed
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Feb 2026
- Primary completion
- Feb 2026
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab, paclitaxel, tegafur in biliary tract adenocarcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Started Feb 2026; status: completed.
02
Drugs
bevacizumabpaclitaxeltegafur
03
Conditions
biliary tract adenocarcinoma
Beyond the preview
Go deeper on NCT07719738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719738.